Table 3 Clinical trial studies related to ctDNA in ovarian cancer patients
From: Prediction of the treatment response in ovarian cancer: a ctDNA approach
| Clinical trial title | Participants | Date | Interventions | Recruitment Status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| Plasma ctDNA detection in diagnosis of epithelial ovarian cancer. (ctDNA_EOC) | 43 | October 19, 2017 | Diagnostic Test: methylation markers screening | Completed | NCT03155451 |
| Study of circulating tumoral DNA in ovarian cancer. | 25 | January 23, 2017 | Blood sampling | Completed | NCT01350908 |
| Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in ovarian cancer. | 160 | October 18, 2018 |
• Drug: Olaparib • Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Recruiting | NCT02822157 |
| Assessment of the minimal residual disease in ovarian cancer from circulating tumor DNA and immune repertoire. | 100 | August 3, 2018 | – | Recruiting | NCT03614689 |
| Circulating tumor DNA as a marker of residual disease & response to adjuvant chemotherapy in stage I-IV ovarian cancer. | 100 | October 1, 2018 | Diagnostic Test: Circulating tumour DNA testing | Recruiting | NCT03691012 |
| Circulating tumor DNA as an early marker of recurrence and treatment efficacy in ovarian carcinoma (CIDOC). | 150 | September 26, 2019 | biological sampling | Recruiting | NCT03302884 |
| Study of the effects of pembrolizumab in patients with advanced solid tumors | 94 | March 21, 2016 | • Biological: Pembrolizumab | Active, not recruiting | NCT02644369 |